LJI Wealth Management LLC Sells 150 Shares of Novo Nordisk A/S (NYSE:NVO)

LJI Wealth Management LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 3.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,230 shares of the company’s stock after selling 150 shares during the period. LJI Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $504,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NVO. RIA Advisory Group LLC bought a new stake in shares of Novo Nordisk A/S during the third quarter worth approximately $281,000. Natixis Advisors LLC grew its holdings in Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after acquiring an additional 80,070 shares during the period. First Long Island Investors LLC bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $3,715,000. Birchcreek Wealth Management LLC lifted its stake in shares of Novo Nordisk A/S by 8.3% in the 3rd quarter. Birchcreek Wealth Management LLC now owns 2,542 shares of the company’s stock valued at $303,000 after purchasing an additional 195 shares during the period. Finally, Sheaff Brock Investment Advisors LLC boosted its position in shares of Novo Nordisk A/S by 4.5% in the 3rd quarter. Sheaff Brock Investment Advisors LLC now owns 3,470 shares of the company’s stock worth $413,000 after purchasing an additional 150 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Down 3.4 %

Shares of NYSE:NVO traded down $3.58 during trading on Friday, hitting $101.74. 8,076,248 shares of the company’s stock traded hands, compared to its average volume of 4,457,389. The company has a 50-day moving average price of $118.58 and a 200-day moving average price of $129.58. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a market cap of $456.56 billion, a price-to-earnings ratio of 32.93, a price-to-earnings-growth ratio of 1.31 and a beta of 0.42.

Analysts Set New Price Targets

A number of research firms recently commented on NVO. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.